Division of Diagnostic Pathology, National Cancer Center Hospital, Tokyo, Japan.
Division of Genome Biology, National Cancer Center Research Institute, Tokyo, Japan.
Pathol Int. 2021 May;71(5):355-359. doi: 10.1111/pin.13082. Epub 2021 Feb 25.
ALK, ROS1 and NTRK fusions are involved in the tumorigenesis of various organs, including colorectal cancer. This study aims to clarify the prevalence of these fusions in colorectal cancer in the Japanese population. Immunohistochemical analysis of 1012 specimens of colorectal cancer revealed two NTRK-positive cases (0.2%) whereas no ALK- or ROS1-positive cases were identified. Reverse transcription polymerase chain reaction (RT-PCR) detected an LMNA-NTRK1 fusion in a case of adenosquamous carcinoma and a TPM3-NTRK1 fusion in a case of tubular adenocarcinoma. Both NTRK1 fusion-positive cases lacked activating mutations in KRAS and BRAF and were mismatch repair-deficient with loss of MLH1 and PMS2 expression and MLH1 promoter methylation. Our results show that receptor tyrosine kinase fusions are rare but present in colorectal cancers in Japanese patients, with a prevalence similar to that reported in other countries.
ALK、ROS1 和 NTRK 融合参与了包括结直肠癌在内的各种器官的肿瘤发生。本研究旨在阐明这些融合在日本人群中的结直肠癌中的流行情况。对 1012 份结直肠癌标本进行免疫组织化学分析,显示有 2 例 NTRK 阳性病例(0.2%),而未发现 ALK-或 ROS1 阳性病例。逆转录聚合酶链反应(RT-PCR)在 1 例腺鳞癌中检测到 LMNA-NTRK1 融合,在 1 例管状腺癌中检测到 TPM3-NTRK1 融合。这两个 NTRK1 融合阳性病例均缺乏 KRAS 和 BRAF 的激活突变,且存在错配修复缺陷,表现为 MLH1 和 PMS2 表达缺失以及 MLH1 启动子甲基化。我们的结果表明,受体酪氨酸激酶融合在日本患者的结直肠癌中较为罕见,但存在,其发生率与其他国家报道的相似。